UBS Group
OVID icon

UBS Group’s Ovid Therapeutics OVID Stock Holding History

UBS Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$616K Buy
277,656
+84,671
+44% +$151K ﹤0.01% 5926
2025
Q4 		$315K Sell
192,985
-44,994
-19% -$69.3K ﹤0.01% 6334
2025
Q3 		$309K Buy
237,979
+216,310
+998% +$187K ﹤0.01% 6419
2025
Q2 		$7.15K Sell
21,669
-5,289
-20% -$1.59K ﹤0.01% 9041
2025
Q1 		$8.41K Sell
26,958
-33,809
-56% -$20.8K ﹤0.01% 8756
2024
Q4 		$56.8K Buy
60,767
+30,155
+99% +$33.7K ﹤0.01% 7222
2024
Q3 		$36.1K Buy
30,612
+9,420
+44% +$9.84K ﹤0.01% 7032
2024
Q2 		$16.3K Sell
21,192
-52,230
-71% -$145K ﹤0.01% 7437
2024
Q1 		$224K Buy
73,422
+1,489
+2% +$4.98K ﹤0.01% 5779
2023
Q4 		$232K Buy
71,933
+23,826
+50% +$81.4K ﹤0.01% 5694
2023
Q3 		$185K Sell
48,107
-1,519
-3% -$5.46K ﹤0.01% 5415
2023
Q2 		$163K Buy
49,626
+31,557
+175% +$107K ﹤0.01% 5622
2023
Q1 		$46.6K Buy
18,069
+1,276
+8% +$3.02K ﹤0.01% 6506
2022
Q4 		$31.2K Sell
16,793
-2,368
-12% -$4.03K ﹤0.01% 7197
2022
Q3 		$36K Buy
19,161
+3,216
+20% +$6.73K ﹤0.01% 6663
2022
Q2 		$34K Buy
15,945
+945
+6% +$2.28K ﹤0.01% 6268
2022
Q1 		$47K Sell
15,000
-4,277
-22% -$13.5K ﹤0.01% 6562
2021
Q4 		$62K Buy
19,277
+4,277
+29% +$14.7K ﹤0.01% 6725
2021
Q3 		$50K Hold
15,000
– – ﹤0.01% 6327
2021
Q2 		$59K Sell
15,000
-5,037
-25% -$19.9K ﹤0.01% 6289
2021
Q1 		$81K Sell
20,037
-1,009,556
-98% -$3.35M ﹤0.01% 6125
2020
Q4 		$2.38M Buy
1,029,593
+579,322
+129% +$2.7M ﹤0.01% 3242
2020
Q3 		$2.58M Buy
450,271
+317,281
+239% +$2.12M ﹤0.01% 2810
2020
Q2 		$980K Sell
132,990
-74,974
-36% -$351K ﹤0.01% 3520
2020
Q1 		$620K Buy
207,964
+203,986
+5,128% +$687K ﹤0.01% 3772
2019
Q4 		$17K Buy
+3,978
New +$12.6K ﹤0.01% 6994
2019
Q3 		– Sell
-6,860
Closed -$13K – 8178
2019
Q2 		$13K Buy
+6,860
New +$12.3K ﹤0.01% 6900
2019
Q1 		– Sell
-10,101
Closed -$24K – 8035
2018
Q4 		$24K Buy
10,101
+6,805
+206% +$31.1K ﹤0.01% 6645
2018
Q3 		$19K Buy
3,296
+322
+11% +$2.44K ﹤0.01% 6826
2018
Q2 		$23K Buy
+2,974
New +$25.5K ﹤0.01% 6604
2018
Q1 		– Sell
-227
Closed -$2K – 8071
2017
Q4 		$2K Sell
227
-1,543
-87% -$14.2K ﹤0.01% 7616
2017
Q3 		$15K Buy
+1,770
New +$14.7K ﹤0.01% 6655

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS Group's OVID Position: Q1 2026 in Review

UBS Group increased its Ovid Therapeutics (OVID) stake by 44% in Q1 2026, buying an estimated $151K and bringing the position to 277,656 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #5926.

UBS Group first reported a position in OVID in Q3 2017 and has held it in 32 quarters since. The position peaked at $2.58M in Q3 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • UBS Group held 277,656 shares of Ovid Therapeutics worth $616K as of Q1 2026.
  • UBS Group bought 84,671 Ovid Therapeutics shares in Q1 2026, an estimated $151K.
  • Ovid Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5926 holding.
  • UBS Group first reported a position in Ovid Therapeutics in Q3 2017 and has held it in 32 quarters since.
  • UBS Group's Ovid Therapeutics position peaked at $2.58M in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.